Article
Medicine, General & Internal
Laetitia Diep, Vincent Barbier, Marie Doussiere, Estelle Touboul, Claire Jesson, Valentine Deprez, Jean-Marc Sobhy-Danial, Patrice Fardellone, Vincent Goeb
Summary: This study compares the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and describes their efficacy and safety profiles. The results show that the 2-year persistence rates for infliximab, abatacept, and tocilizumab did not differ significantly, confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant improvement in Disease-Activity Score-28 (DAS28) at 2 years compared to infliximab and abatacept.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Medicine, General & Internal
Alberto Floris, Daniela Perra, Ignazio Cangemi, Mattia Congia, Elisabetta Chessa, Maria Maddalena Angioni, Arduino Aleksander Mangoni, Gian Luca Erre, Alessandro Mathieu, Matteo Piga, Alberto Cauli
Summary: The study identified current smoking as a predictor of inadequate response to methotrexate in rheumatoid arthritis patients. Other independent predictors of treatment response were also found, which may assist in personalized monitoring of RA patients. Further research is needed to investigate whether smoking cessation strategies enhance the therapeutic response to methotrexate.
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Yoshiya Tanaka, Tsukasa Matsubara, Koichi Hashizume, Norihito Amano, Tsutomu Takeuchi
Summary: The objective of this study was to evaluate the efficacy and safety of abatacept in biologic-naive ACPA-positive Japanese patients with active RA. The results showed that regardless of baseline MTX dose, abatacept demonstrated similar efficacy and safety.
MODERN RHEUMATOLOGY
(2022)
Article
Rheumatology
Paul Studenic, Gregor Bond, Andreas Kerschbaumer, Manuel Becede, Karel Pavelka, Dmitry Karateev, Jutta Stieger, Rudolf Puchner, Ruediger B. Mueller, Elisabeth Puchhammer-Stoeckl, Martina Durechova, Michaela Loiskandl, Thomas Perkmann, Martina Olejarova, Elena Luchikhina, Carl-Walter Steiner, Michael Bonelli, Josef S. Smolen, Daniel Aletaha
Summary: The study found that TTV levels increase and are associated with clinical response in RA patients who fail to respond to MTX and receive bDMARDs treatment.
Article
Rheumatology
Chun Wu, Yanhua Hu, Peter Schafer, Sean E. Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, Clifton O. Bingham, Thomas W. J. Huizinga, Roy Fleischmann, Jinqi Liu
Summary: This study aimed to investigate the correlations between biomarkers of bone remodelling and extracellular matrix turnover with baseline disease activity and treatment response in patients with early RA. The results showed that baseline levels of CTX-I were significantly associated with treatment response to abatacept+MTX, suggesting that CTX-I could be a potential predictor for treatment response in early RA patients.
Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
Summary: Methotrexate is associated with rare bone lesions that are often misdiagnosed as osteoporotic fractures. Early diagnosis is crucial for treatment and prevention of further osteopathology. This case highlights the importance of raising awareness and taking appropriate therapeutic measures, including discontinuing methotrexate.
Article
Chemistry, Analytical
Junqing He, Junyan Wang, Min Zhang, Guoyue Shi
Summary: As a folate antagonist, methotrexate (MTX) has been widely used in clinics for treating various tumors and inflammatory diseases. However, the dosage and clearance of MTX vary between individuals, and it may cause life-threatening side effects at high doses. Therefore, a convenient and simple method for MTX sensing is highly demanded.
Article
Rheumatology
Clement Triaille, Gaelle Tilman, Tatiana Sokolova, Axelle Loriot, Joelle Marchandise, Stephanie De Montjoye, Adrien Nzeusseu-Toukap, Laurent Meric de Bellefon, Caroline Bouzin, Christine Galant, Patrick Durez, Bernard R. Lauwerys, Nisha Limaye
Summary: This study used transcriptomic profiling to explore clinically relevant subgroups in early, untreated rheumatoid arthritis (RA) patients. The synovial transcriptome closely mirrored clinical disease activity, and the ratio of M2:M1 macrophages was inversely correlated with inflammation and disease activity, suggesting a protective role for tissue resident macrophages in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Carlos Fernandez-Diaz, Belen Atienza-Mateo, Santos Castaneda, Rafael B. Melero-Gonzalez, Francisco Ortiz-SanJuan, Javier Loricera, Ivette Casafont-Sole, Sebastian Rodriguez-Garcia, Clara Aguilera-Cros, Ignacio Villa-Blanco, Enrique Raya-Alvarez, Clara Ojeda-Garcia, Gema Bonilla, Alejandra Lopez-Robles, Luis Arboleya, Javier Narvaez, Evelin Cervantes, Olga Maiz, Maria N. Alvarez-Rivas, Ivan Cabezas, Eva Salgado, Cristina Hidalgo-Calleja, Sabela Fernandez, Jesus C. Fernandez, Ivan Ferraz-Amaro, Miguel A. Gonzalez-Gay, Ricardo Blanco
Summary: In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or other conventional DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA.
Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Multidisciplinary Sciences
Helen R. Gosselt, Costanza L. Vallerga, Pooja R. Mandaviya, Erik Lubberts, Johanna M. W. Hazes, Robert de Jonge, Sandra G. Heil
Summary: The study did not identify genome-wide significant differences as biomarkers for Methotrexate (MTX) therapy response, necessitating meta-analyses.